Land: Canada
Sprog: engelsk
Kilde: Health Canada
DIMETHYL FUMARATE
ACCORD HEALTHCARE INC
L04AX07
DIMETHYL FUMARATE
240MG
CAPSULE (DELAYED RELEASE)
DIMETHYL FUMARATE 240MG
ORAL
15G/50G
Prescription
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Active ingredient group (AIG) number: 0154210002; AHFS:
APPROVED
2021-10-04
_ACH-DIMETHYL FUMARATE (dimethyl fumarate delayed-release capsules) _ _Page 1 of 47 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr ACH-DIMETHYL FUMARATE Dimethyl Fumarate Delayed-Release Capsules delayed-release capsules, 120 mg and 240 mg Antineoplastic and Immunomodulating Agents Accord Healthcare Inc. 3535 boul. St. Charles, Suite 704 Kirkland, QC, H9H 5B9 Canada Submission Control No: 276792 Date of Initial Authorization: OCT 4, 2021 Date of Revision: OCT 10, 2023 _ACH-DIMETHYL FUMARATE (dimethyl fumarate delayed-release capsules) _ _Page 2 of 47 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 10/2023 8 ADVERSE REACTIONS, 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data 10/2023 10 CLINICAL PHARMACOLOGY, 10.2 Pharmacodynamics 10/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................... 5 4.1 Dosing Considerations .............................................................................................. Læs hele dokumentet